

ALLEGATO B

UNIVERSITÀ DEGLI STUDI DI MILANO

selezione pubblica per n._1_ posto/i di Ricercatore a tempo determinato ai sensi dell'art.24, comma 3, lettera b) della Legge 240/2010 per il settore concorsuale ____06/B1, settore scientifico-disciplinare _____Medicina Interna_____
presso il Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
(avviso bando pubblicato sulla G.U. n. ____81____ del _12/10/2018_____) Codice
concorso ____3947____

[Rosa Lombardi] CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	LOMBARDI
NOME	ROSA
DATA DI NASCITA	[20, APRILE, 1984]

CURRICULUM VITAE

PERSONAL DETAILS

Name: Rosa Lombardi

Place of birth: Cernusco Sul Naviglio (Milan)

Date of birth: 20th April 1984

ADDRESS: *University of Milan- IRCCS Ca' Granda Foundation Policlinico*

Hospital Department of Pathophysiology and Transplantantation

Metabolic and Liver Diseases Research Center

Via F Sforza 35-20122 Milan Italy

EMAIL: rosa.lombardi@unimi.it; rosalombardi@hotmail.it

• Italian medical license to practice:

Ordine dei Medici Chirurghi e Odontoiatri di Milano n 41985 (september 2010)

EDUCATION AND TRAINING

• Scientific High school degree (100/100).

• Degree in Medicine and Surgery (110/110 cum laude) at University of the Study of Milan in March 2010

Thesis title: "STEATOSI EPATICA NON ALCOLICA E RISCHIO CARDIOVASCOLARE IN SOGGETTI CON SINDROME METABOLICA: STUDIO PILOTA SULLA VALUTAZIONE DEL GRASSO EPICARDICO COME NUOVO INDICE DI AUMENTATO GRASSO VISCERALE". (Non-alcoholic fatty disease and cardiovascular risk in subjects with metabolic syndrome: pilot study on the evaluation of epicardial fat as new index of increased visceral adipose tissue"

• Postgraduate in Internal Medicine at University of Milan (70/70 cum laude) in July 2016

Thesis title: "IL DANNO EPATICO NEL PAZIENTE DIABETICO: DIAGNOSI NON INVASIVA DI STEATOSI E FIBROSI" (Liver damage in diabetes: non-invasive diagnosis of steatosis and fibrosis")

• **Clinical and Research Fellow** (October 2014 to October 2015). University College of London (UCL) Institute for Liver and Digestive Health, **Royal Free Hospital**, London (United Kingdom). Chief Prof. Massimo Pinzani, Tutor Dr. Emmanouil Tsochatzis: where her activity was:

- Clinical activity at the general hepatology clinic, NAFLD clinic and the Ward of hepatology. Weekly training sessions with histology, radiology and liver transplant seminars
- Clinical and technical training in the use of transient elastography (FibroScan®)
- Clinical research on non-invasive assessment of liver disease and liver fibrosis, especially in NAFLD patients and in HIV mono-infected patients and publication of several scientific papers.
- Cochrane metanalysis on drug interventions in NAFLD

• **United Kingdom medical license to practice:** General Medical Council (GMC) n 7486683 (may 2015).

• **Post-Hoc Fellow at University of the Study of Milan** (From 1st February 2017 onwards).

Clinical research activity at the Metabolic and Liver diseases outpatient Service, IRCCS Foundation Ca'Granda Policlinico of Milan, Milan. Chief Prof.S.Fargion.

WORK EXPERIENCE

- **Clinical and Research Fellow** (July 2010 to June 2011) at Metabolic and Liver diseases outpatient Service, IRCCS Foundation Ca'Granda Policlinico of Milan, Milan. Chief Prof.S.Fargion.
- **Consultant physician** (1st July to 31th December 2017) at the Emergency Department, IRCCS Foundation Ca'Granda Policlinico of Milan, Milan.
- **Consultant physician** (8th January to 8th March 2018) at the Internal Medicine Unit (Immunology and Allergology department), IRCCS Foundation Ca'Granda Policlinico of Milan, Milan.
- **Consultant physician** at the Hepatology and Metabolic diseases outpatient Service_(21th May 2018 onwards) at IRCCS Foundation Ca'Granda Policlinico of Milan, Milan.

Liver and metabolic disorders clinic and hepatology day care. In particular, general hepatology clinic, viral hepatitis clinic and NAFLD clinic.

Nutritional therapy clinic (also with the use of body bioelectrical impedance test and Arm Band)

Diabetes clinic

Ultrasound and Doppler US and liver transient elastography (FibroScan®) outpatient services

Study coordinator and **sub-investigator** in **pharmacological clinical trials** for the treatment of non-alcoholic steatohepatitis (NASH)

PROFESSIONAL MEMBERSHIP-SCIENTIFIC SOCIETY

- AISF (Italian Association Study of Liver)
- SIMI (Italian Association Internal Medicine),
- EASL (European Association Study Liver)
- AASLD (American Association Study Liver Disease)
- EFIM (European Federation Internal Medicine)
- Cochrane metanalysis on drug interventions in NAFLD

CERTIFICATIONS

- National Certification of **Clinic Ultrasound** by SIUMB (October 2018).

- **EASL Hepatology MASTERCLASS.** Advanced course in Hepatology. Participation as speaker, presenting a study on liver fibrosis in patients with HIV mono-infection". December 2015, Pavia (Italy).
- Certification of **Cerner's Millennium Clinician's Course.** July 2015, Royal Free Hospital, NHS Foundation Trust, London (United Kingdom).
- Certification of **Hepatology Postgraduate Course EASL** (European Association for the Study of the Liver). Advanced course in Hepatology. April 2015, Royal Free Hospital, London (United Kingdom).
- Certification of **Clinic Ultrasound:** "Summer school of clinic ultrasound" by SIMI (Italian Society of Internal Medicine). May 2014, Monterenzio (Bologna, Italy).
- Advanced theoretical-practical course on **Ultrasound Doppler** of carotid and vertebral arteries and **transcranial sonography**; February 2014, Milan (Italy).
- Course on Non-invasive Ventilation (**NIV**), by SIMEU; November 2013, Milan (Italy).
- Course on techniques and procedures in critical patients, by SIMEU (Italian Society of Emergency and Urgency Medicine) society; January 2013, Naples (Italy).

CONGRESS and CONFERENCE PARTICIPATIONS

- **The International Liver Congress by EASL.** Oral communication "Lean-non alcoholic fatty liver disease (NAFLD) with central visceral obesity identifies patients with more severe disease" and as poster session. April 2016, Barcelona (Spain).
- **EFIM** (European Federation of Internal Medicine) **Winter School** organized by European Society of Internal Medicine (ESIM). Oral communication "A strange case of deep venous thromboembolism-extrapulmonary tuberculosis". February 2015, Riga (Latvia).
- **SISA** (Italian Society for the Study of Atherosclerosis) regional congress on "The patient at high cardiovascular risk: an integrative approach". Oral Communication "Spessore grasso epicardico mediante ecocardiografia nella steatosi epatica non alcolica (NAFLD): possibile marcatore di sindrome metabolica e danno vascolare precoce". April 2011, Milan (Italy).
- **SIMI** (Italian Society of Internal Medicine) National Congress, oral communication " Echocardiographic epicardial fat thickness: preliminary results of a prospective study in non alcoholic fatty liver disease". October 2010, Rome (Italy).
- Scientific work presented at many National and International congresses as Poster Session. (EASL; AISF- Italian Association for the Study of the Liver; SIMI-Italian Society of Internal Medicine; EFIM)

Clinical trials involved in phase III clinical medical trials of new drugs for the treatment of non-alcoholic steatohepatitis (NASH). ICH GOOD CLINICAL PRACTICE E6(R2) (10/05/2018) n 402511

Research topic:

Research focused on hepatology (mainly non-alcoholic fatty liver disease-NAFLD and steatohepatitis-NASH), insulin resistance and type 2 diabetes. In particular, interest in non-invasive assessment of liver disease and liver fibrosis, especially in NAFLD patients and diabetic patients. Evaluation of NAFLD main complications (cardiovascular damage and hepatocellular carcinoma). Metabolic liver disease in HIV infected patients

Reviewer activity for peer review Journal: Digestive and Liver Disease; Liver International.

Publications: 16 publications in peer reviewed Journals; 2 papers in press. IF: 56.148; H-index: 9 (Scopus); 7 (Web of science)

List of Publications:

1. Pelusi S, Iuculano F, Lombardi R, Francione P, Gianelli U, Fracanzani AL, Fargion S. *Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis*. Intern Emerg Med. 2018; (ahead of print). IF 2.453.
2. Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, Biondetti P, Fargion S, Fracanzani AL. *Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis*. Atherosclerosis. 2018; 268:27-31. IF 4.239.
3. Pigoni A, Iuculano F, Saetti C, Airaghi L, Burdick L, Spreafico S, Curioni M, Lombardi R, Valenti L, Fracanzani AL, Fargion S. *Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease*. Metab Brain Dis. 2018; 33 (1): 347-352. IF 2.297
4. Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxi A, Fargion S. *Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity*. Clin Gastroenterol Hepatol. 2017;15(10):1604-1611. IF 7.680.
5. Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. *Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis*. Cochrane Database Syst Rev. 2017;3:CD011640. doi: 10.1002/14651858.CD011640.pub2. IF 6.124.
6. Lombardi R, Lever R, Smith C, Marshall N, Rodger A, Bhagani S, Tsochatzis E. *Liver test abnormalities in patients with HIV mono-infection: assessment with simple non-invasive fibrosis markers*. Ann Gastro 2017;30(3):349-356. Cite Score 1.94.
7. Pelusi S, Lombardi R, Airaghi L, Burdick L, Rango M, Penatti A, Fargion S. *Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis*. J Res Med Sci. 2016 7(21):117. IF 1.237.
8. Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. *Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection*. Dig Liver Dis. 2016; 48 (12): 1471-1477. IF 3.061
9. Pisano G, Lombardi R, Fracanzani AL. *Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin*. Int J Mol Sci. 2016;17(5):675. IF 3.226
10. Lombardi R, Pisano G, Fargion S. *Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD*. Int J Mol Sci. 2016;17(4):548. IF 3.226
11. Lombardi R, Buzzetti E, Roccarina D, Tsochatzis EA. *Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease*. World J Gastroenterol. 2015;21(39):11044-11052. IF 3.365

12. Papastergiou V, Lombardi R, MacDonald D, Tsochatzis EA; *Global Epidemiology of Hepatitis B Virus (HBV) Infection*. Curr Hepatol Rep. 2015; 14:171–178. IF 2.60
13. Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. *Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease*. Int J Endocrinol. 2015;2015:343828. IF 2.51.
14. Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A, Fargion S, Sesti G, Valenti L *The UCP2-886 G>A promoter region polymorphism is associated with non-alcoholic steatohepatitis*. Liver Int. 2015;35(5):1574-1580. IF 4.116
15. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. *J PNPLA3 I148M polymorphism and progressive liver disease*. World J Gastroenterol. 2013;19(41):6969-6978. Review. IF 3.365
16. Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G, Fargion S. *Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity*. J Hepatol 2011;54(6):1244-1249. IF 13.24

In press:

1. Tiraboschi S, Marzano AV, Lombardi R, Genovese G, Boccoli G, Fargion S, Fracanzani AL. *“A sweet fever”*. Intern Emerg Med. 2018. IF2.453.
2. Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxi A, Fargion S, Fracanzani AL. *“Fibroscan detects cardiovascular damage in NAFLD patients”*. Clin Gastroenterol Hepatol 2018. IF 7.683.

KNOWLEDGE OF FOREIGN LANGUAGES

English: IELTS certificate score 8.0/9.0, January 2015, London (UK)

Data

07/11/2018

Luogo

Milano